SP2

Summary

SP2 (Sp2 transcription factor, HGNC:11207) is a protein-coding gene on chromosome 17q21.32, encoding Transcription factor Sp2 (Q02086). Binds to GC box promoters elements and selectively activates mRNA synthesis from genes that contain functional recognition sites. It is a selective cancer dependency (DepMap: 12.7% of cell lines).

This gene encodes a member of the Sp subfamily of Sp/XKLF transcription factors. Sp family proteins are sequence-specific DNA-binding proteins characterized by an amino-terminal trans-activation domain and three carboxy-terminal zinc finger motifs. This protein contains the least conserved DNA-binding domain within the Sp subfamily of proteins, and its DNA sequence specificity differs from the other Sp proteins. It localizes primarily within subnuclear foci associated with the nuclear matrix, and can activate or in some cases repress expression from different promoters.

Source: NCBI Gene 6668 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 82 total
• Cancer dependency (DepMap): dependent in 12.7% of screened cell lines
• Transcription factor: yes — 26 downstream targets (CollecTRI)
• MANE Select transcript: NM_003110

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11207
Approved symbol	SP2
Name	Sp2 transcription factor
Location	17q21.32
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0048
Ensembl gene	ENSG00000167182
Ensembl biotype	protein_coding
OMIM	601801
Entrez	6668

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000376741, ENST00000635868, ENST00000637314, ENST00000637943, ENST00000642065, ENST00000884861, ENST00000884862, ENST00000884863

RefSeq mRNA: 1 — MANE Select: NM_003110 NM_003110

CCDS: CCDS11521

Canonical transcript exons

ENST00000376741 — 7 exons

Exon	Start	End
ENSE00000812563	47925348	47925541
ENSE00000947318	47924919	47925093
ENSE00001137543	47922962	47923274
ENSE00001194271	47927724	47928957
ENSE00001413539	47916156	47917130
ENSE00002449690	47915312	47915388
ENSE00002729406	47896236	47896293

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 92.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.1494 / max 105.9616, expressed in 1786 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161386	14.9545	1784
161387	0.1949	73

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	92.17	gold quality
buccal mucosa cell	CL:0002336	92.16	gold quality
granulocyte	CL:0000094	88.27	gold quality
right testis	UBERON:0004534	88.01	gold quality
left testis	UBERON:0004533	87.51	gold quality
gastrocnemius	UBERON:0001388	86.99	gold quality
popliteal artery	UBERON:0002250	86.95	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.94	gold quality
tibial artery	UBERON:0007610	86.94	gold quality
oocyte	CL:0000023	86.92	gold quality
leukocyte	CL:0000738	86.82	gold quality
monocyte	CL:0000576	86.68	gold quality
mononuclear cell	CL:0000842	86.65	gold quality
muscle of leg	UBERON:0001383	86.53	gold quality
blood	UBERON:0000178	86.21	gold quality
endometrium epithelium	UBERON:0004811	86.01	gold quality
aorta	UBERON:0000947	85.97	gold quality
synovial joint	UBERON:0002217	85.93	gold quality
right coronary artery	UBERON:0001625	85.67	gold quality
testis	UBERON:0000473	85.63	gold quality
right lung	UBERON:0002167	85.52	gold quality
vermiform appendix	UBERON:0001154	85.38	gold quality
right lobe of thyroid gland	UBERON:0001119	85.36	gold quality
left lobe of thyroid gland	UBERON:0001120	85.35	gold quality
left uterine tube	UBERON:0001303	85.29	gold quality
descending thoracic aorta	UBERON:0002345	85.25	gold quality
thymus	UBERON:0002370	85.19	gold quality
parotid gland	UBERON:0001831	85.00	silver quality
penis	UBERON:0000989	84.90	gold quality
heart left ventricle	UBERON:0002084	84.83	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.58
E-GEOD-100618	no	67.08

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

26 targets.

Target	Regulation
ALOX15B
CCND1	Unknown
CD14	Unknown
CDKN1A	Unknown
CDKN2A
CEACAM1	Repression
CTSL	Unknown
DHFR	Activation
DNMT3A	Activation
DNMT3B	Activation
HBB
HSD17B2	Repression
KLK3
MAT2A	Unknown
MIR638
MMP9	Repression
NFATC2	Unknown
NFKB
PAPSS1
PAPSS2	Unknown
PCYT1A	Repression
POLD1
SOCS1
SP1
TFAP2A
TSC1

JASPAR motifs

Motif	Name	Family
MA0516.1	SP2	Three-zinc finger Kruppel-related
MA0516.2	SP2	Three-zinc finger Kruppel-related
MA0516.3	SP2	Three-zinc finger Kruppel-related

JASPAR matrix evidence (PMIDs): PMID:22684502, PMID:14726517

Upstream regulators (CollecTRI, top): NFKB, SP1, TFAP2A

miRNA regulators (miRDB)

83 targeting SP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-LET-7A-3P	100.00	74.03	3932
HSA-MIR-3689D	100.00	66.14	1181
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-1321	99.84	65.30	1811

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 11)

• has an intimate part in transcriptional regulation of the lh receptor gene. (PMID:15788387)
• an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration (PMID:17071613)
• Despite the absence of Sp2 in the 5’-upstream sequence of the human promoter, silencing of Sp2 by RNA interference clearly demonstrated that Sp2 is required for IFN-gamma-induced regulation of socs1 mRNA both in human and mouse. (PMID:19482358)
• Data show that three Sp1 motifs located between -148 and -42bp upstream of the first exon were important in basic as well as in DA-induced NSMase2 promoter activity. (PMID:19698806)
• Sp2 is up-regulated in gastric cancer tissues (PMID:24623314)
• O-GlcNAc modification of Sp3 and Sp4, but not Sp2 transcription factors negatively regulates their transcriptional activities. (PMID:26431879)
• This study presented that a Novel Mutation (Gly212Val) in the PS2 Gene Associated with Early-Onset Familial Alzheimer’s Disease. (PMID:27128372)
• SP2 recognized binding motifs in the human RORgammaT promoter, which was critical for maintaining expression. SP2 was necessary for maximum IL-17 expression in in vitro-differentiated Th17 cells. SP 2 plays a role in Th17-dependent physiologic and pathologic immune responses. (PMID:27256574)
• Sp2 promotes invasion and metastasis of hepatocellular carcinoma by targeting TRIB3 protein. (PMID:32160655)
• Transcription Factor SP2 Regulates Ski-mediated Astrocyte Proliferation In Vitro. (PMID:34687796)
• Transcription factor Sp2 promotes TGFB-mediated interstitial cell osteogenic differentiation in bicuspid aortic valves through a SMAD-dependent pathway. (PMID:34914964)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	sp2	ENSDARG00000076763
mus_musculus	Sp2	ENSMUSG00000018678
rattus_norvegicus	Sp2	ENSRNOG00000010492

Paralogs (3): SP4 (ENSG00000105866), SP3 (ENSG00000172845), SP1 (ENSG00000185591)

Protein

Protein identifiers

Transcription factor Sp2 — Q02086 (reviewed: Q02086)

All UniProt accessions (5): A0A1B0GTK3, A0A1B0GV29, A0A1B0GVH1, A0A286YFJ7, Q02086

UniProt curated annotations — full annotation on UniProt →

Function. Binds to GC box promoters elements and selectively activates mRNA synthesis from genes that contain functional recognition sites.

Subcellular location. Nucleus.

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. In SP2, the motif is inactive.

Similarity. Belongs to the Sp1 C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q02086-1	1	yes
Q02086-2	2

RefSeq proteins (1): NP_003101* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (13 total): zinc finger region 3, compositionally biased region 3, region of interest 3, chain 1, modified residue 1, splice variant 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q02086-F1	45.39	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 78

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 140 (showing top): CCAWYNNGAAR_UNKNOWN, TGACCTY_ERR1_Q2, GGGTGGRR_PAX4_03, GGAMTNNNNNTCCY_UNKNOWN, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GCM_RING1, ACATTCC_MIR1_MIR206, MORF_PPP6C, RYTTCCTG_ETS2_B, ACTTTAT_MIR1425P, CUI_TCF21_TARGETS_2_DN, ACEVEDO_LIVER_CANCER_UP, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, TGCCTTA_MIR124A, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), immune response (GO:0006955)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), histone deacetylase binding (GO:0042826), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): chromatin (GO:0000785), nucleoplasm (GO:0005654), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
immune system process	1
response to stimulus	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
enzyme binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosome	1
nuclear lumen	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

576 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SP2	POLRMT	O00411	694
SP2	TFB2M	Q9H5Q4	677
SP2	MTERF1	Q99551	657
SP2	TEFM	Q96QE5	583
SP2	TFB1M	Q8WVM0	582
SP2	TFAM	Q00059	580
SP2	MT-ND6	P03923	542
SP2	E2F1	Q01094	450
SP2	MTERF3	Q96E29	432
SP2	FANCD2OS	Q96PS1	414
SP2	MT-CO1	P00395	400
SP2	MT-ND5	P03915	386
SP2	WAC	Q9BTA9	385
SP2	ELAC2	Q9BQ52	379
SP2	ZNF263	O14978	375

IntAct

31 interactions, top by confidence:

A	B	Type	Score
BANP	SP2	psi-mi:“MI:0915”(physical association)	0.670
FHL2	SP2	psi-mi:“MI:0915”(physical association)	0.670
SP2	FHL2	psi-mi:“MI:0915”(physical association)	0.670
SP2	BANP	psi-mi:“MI:0915”(physical association)	0.670
MCM7	SP2	psi-mi:“MI:0915”(physical association)	0.560
SP2	MCM7	psi-mi:“MI:0915”(physical association)	0.560
FHL2	CNOT1	psi-mi:“MI:0914”(association)	0.530
VWCE	ZNF316	psi-mi:“MI:0914”(association)	0.530
P		psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
SP1	PPP6C	psi-mi:“MI:0914”(association)	0.350
SP2	SHTN1	psi-mi:“MI:0914”(association)	0.350
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
TNFRSF1B	MAP3K7	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
KLF15	ZNF292	psi-mi:“MI:2364”(proximity)	0.270
SRF	ZNF292	psi-mi:“MI:2364”(proximity)	0.270
ELF4	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
ELK3	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
FEV	TAF4	psi-mi:“MI:2364”(proximity)	0.270
NFYC	ASDURF	psi-mi:“MI:2364”(proximity)	0.270
GPKOW	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
PPIL4	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
ZRANB2	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
NPM1	SBNO1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (53): SP2 (Two-hybrid), SP2 (Two-hybrid), BANP (Two-hybrid), SP2 (Two-hybrid), SP2 (Two-hybrid), SP2 (Affinity Capture-MS), SP2 (Affinity Capture-MS), SP2 (Affinity Capture-MS), SP2 (Two-hybrid), SP2 (Two-hybrid), SP2 (Two-hybrid), SP2 (Two-hybrid), BANP (Two-hybrid), QRICH1 (Two-hybrid), SP2 (Affinity Capture-Western)

ESM2 similar proteins: A1Z9E2, B0R0I6, B5DE69, G5ED89, O94842, P25425, P32519, P34333, P34447, Q02086, Q08CM4, Q09XV5, Q0IHV2, Q0P5K4, Q0V9U1, Q15723, Q28BL7, Q3TUF7, Q571G4, Q5E9U0, Q5F3U0, Q5R6A9, Q5RBN8, Q5RCV7, Q60775, Q641Z1, Q6DJM6, Q6IQU7, Q6MZP7, Q7Z589, Q7ZUV7, Q7ZX03, Q86NP2, Q8AYC1, Q8BIH0, Q8BMB0, Q8BU11, Q8CHI8, Q8IRW8, Q8WNV2

Diamond homologs: A5ABV9, B5DE03, B7ZSG3, O08584, O08876, O14901, O35738, O35819, O43474, O62259, O62651, O70494, O75840, O89090, O89091, O95600, P08047, P0CG40, P19544, P22561, P46099, P49952, P49953, P50902, P57682, P58334, P79958, Q01714, Q02086, Q02446, Q02447, Q0VA40, Q13118, Q13351, Q13887, Q14V87, Q19A40, Q19A41, Q22678, Q24266

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SP2	“up-regulates activity”	IRF1	binding
SP2	“down-regulates quantity by repression”	PCYT1A	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	71
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1499 predictions. Top by Δscore:

Variant	Effect	Δscore
17:47896272:G:T	donor_gain	1.0000
17:47896275:G:GT	donor_gain	1.0000
17:47896291:GCG:G	donor_gain	1.0000
17:47896343:G:GT	donor_gain	1.0000
17:47897794:A:AG	acceptor_gain	1.0000
17:47897795:A:G	acceptor_gain	1.0000
17:47914836:GAT:G	donor_gain	1.0000
17:47922956:TCCCA:T	acceptor_loss	1.0000
17:47922957:CCCA:C	acceptor_loss	1.0000
17:47922958:CCAG:C	acceptor_loss	1.0000
17:47922959:CAG:C	acceptor_loss	1.0000
17:47922960:AGG:A	acceptor_loss	1.0000
17:47922961:G:GT	acceptor_loss	1.0000
17:47923231:TGTCC:T	donor_gain	1.0000
17:47923272:GCG:G	donor_gain	1.0000
17:47924908:T:A	acceptor_gain	1.0000
17:47924915:ACAG:A	acceptor_gain	1.0000
17:47924915:ACAGG:A	acceptor_gain	1.0000
17:47924916:C:G	acceptor_gain	1.0000
17:47924917:A:AG	acceptor_gain	1.0000
17:47924917:A:C	acceptor_loss	1.0000
17:47924917:AG:A	acceptor_gain	1.0000
17:47924917:AGG:A	acceptor_gain	1.0000
17:47924918:G:A	acceptor_gain	1.0000
17:47924918:G:GG	acceptor_gain	1.0000
17:47924918:GGG:G	acceptor_gain	1.0000
17:47924918:GGGC:G	acceptor_gain	1.0000
17:47924918:GGGCA:G	acceptor_gain	1.0000
17:47925089:AAGAG:A	donor_loss	1.0000
17:47925090:AGAGG:A	donor_loss	1.0000

AlphaMissense

3990 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:47925379:T:A	C527S	1.000
17:47925379:T:C	C527R	1.000
17:47925380:G:A	C527Y	1.000
17:47925380:G:C	C527S	1.000
17:47925381:C:G	C527W	1.000
17:47925394:T:A	C532S	1.000
17:47925394:T:C	C532R	1.000
17:47925395:G:A	C532Y	1.000
17:47925395:G:C	C532S	1.000
17:47925396:T:G	C532W	1.000
17:47925406:T:C	F536L	1.000
17:47925407:T:C	F536S	1.000
17:47925408:C:A	F536L	1.000
17:47925408:C:G	F536L	1.000
17:47925425:T:C	L542P	1.000
17:47925463:T:C	F555L	1.000
17:47925465:T:A	F555L	1.000
17:47925465:T:G	F555L	1.000
17:47925469:T:C	C557R	1.000
17:47925470:G:A	C557Y	1.000
17:47925471:C:G	C557W	1.000
17:47925484:T:C	C562R	1.000
17:47925485:G:A	C562Y	1.000
17:47925486:T:G	C562W	1.000
17:47925496:T:C	F566L	1.000
17:47925497:T:C	F566S	1.000
17:47925498:C:A	F566L	1.000
17:47925498:C:G	F566L	1.000
17:47925515:T:C	L572P	1.000
17:47925525:T:A	H575Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000097487 (17:47907147 A>G), RS1000160162 (17:47928874 A>G), RS1000206700 (17:47924371 A>G), RS1000243325 (17:47907140 T>A,C), RS1000289321 (17:47895435 G>A,C), RS1000475640 (17:47926678 T>C), RS1000501187 (17:47895927 G>A), RS1000941023 (17:47913560 T>G), RS1000952242 (17:47913924 A>G), RS1000976505 (17:47920932 C>T), RS1001186601 (17:47913571 C>T), RS1001222480 (17:47906663 C>T), RS1001248237 (17:47906828 G>A), RS1001299627 (17:47906247 A>G), RS1001439079 (17:47906994 C>A,T)

Disease associations

OMIM: gene MIM:601801 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST005146_34	Birth weight	3.000000e-09
GCST005951_17	Body mass index	3.000000e-09
GCST006075_22	Hair color	4.000000e-90
GCST006988_22	Blond vs. brown/black hair color	9.000000e-16
GCST011457_21	Asthma with severe exacerbations	8.000000e-07
GCST90002409_45	Childhood body mass index	8.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004344	birth weight
EFO:0004340	body mass index
EFO:0003924	hair color

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
tanshinone	decreases expression	1
4-hydroxy-2-nonenal	decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
jinfukang	affects cotreatment, decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Folic Acid	decreases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Urethane	increases expression	1
Valproic Acid	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Chlorodiphenyl (54% Chlorine)	increases expression	1
tert-Butylhydroperoxide	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_HC93	HEK293 eGFP-SP2	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.